Search

Background Presence of inferior vena cava tumor thrombosis (IVCTT) is an unfavorable factor to prognosis for patients with hepatocellular carcinoma (HCC). Case presentation Herein we report a case of HCC with IVC tumor thrombosis extending from the right hepatic vein (RHV) to the IVC, but it had not infiltrated the right atrium. Anterior approach right hepatectomy combined with IVC thrombectomy using trans-diaphragmatic IVC occlusion was performed for this patient. The patient is alive with disease-free at 32 months after treatment. A literature review was also performed. This case was demonstrated with the details and concepts of surgery. Conclusion This case suggested that surgical resection of HCC involving the IVC, but still outside the right atrium (RA), could offer satisfactory surgical outcomes in selected patients.

Molecular variation of different geographic populations and cholangiocarcinoma (CCA) subtypes indicate CCA’s potential genomic heterogeneity and novel genomic features. We analyzed exome-sequencing data of 87 perihialr cholangiocarcinoma (pCCA) and 261 intrahepatic cholangiocarcinoma (iCCA) from 3 Asian centers (including 43 pCCAs and 24 iCCAs from our center). Patients with iCCA presented higher tumor mutation burden and copy number alteration burden (CNAB) than pCCA patients, and CNAB indicated a poorer pCCA prognosis. In our newly identified 12 significantly mutated genes and 5 focal CNA regions, post-transcriptional modification-related novel driver genes METTL14 and RBM10 are prone to occur in pCCA. We demonstrated the tumor-suppressing functional role of METTL14, a major RNA N6-adenosine methyltransferase (m6A), and its loss-of-function mutation R298H may function through m6A modification on new driver gene MACF1. Our results may be valuable for better understanding of post-transcriptional modification effects CCA development, and similarities and differences between pCCA and iCCA.

Molecular variation between geographical populations and subtypes indicate potential genomic heterogeneity and novel genomic features within CCA. Here, we analyze exome-sequencing data of 87 perihilar cholangiocarcinoma (pCCA) and 261 intrahepatic cholangiocarcinoma (iCCA) cases from 3 Asian centers (including 43 pCCAs and 24 iCCAs from our center). iCCA tumours demonstrate a higher tumor mutation burden and copy number alteration burden (CNAB) than pCCA tumours, and high CNAB indicates a poorer pCCA prognosis. We identify 12 significantly mutated genes and 5 focal CNA regions, and demonstrate common mutations in post-transcriptional modification-related potential driver genes METTL14 and RBM10 in pCCA tumours. Finally we demonstrate the tumour-suppressive role of METTL14, a major RNA N6-adenosine methyltransferase (m6A), and illustrate that its loss-of-function mutation R298H may act through m6A modification on potential driver gene MACF1. Our results may be valuable for better understanding of how post-transcriptional modification can affect CCA development, and highlight both similarities and differences between pCCA and iCCA.

Enterprise Information Systems (IS) have been widely applied to improve enterprise performance in the digital era. Users’ behavior is the key for IS success. However, extant research on IS users’ behavior has focused on the in-role behaviors such as IS adoption and usage, while the IS voice behavior which belongs to the extra-role behaviors has been paid little attention to. Employees’ voice is one of the sources of enterprise innovation, and is important for IS success. To fill the research gap and provide several implications for enterprise IS practice, this paper analyzes the antecedents of enterprise IS users’ voice behavior. Based on the work of behavior theory, hypotheses are proposed. Regression is conducted to test the hypotheses with the samples of 187 enterprise IS users by a survey. The results show that organizational innovation climate, positive emotion, perceived ease of use, and extroversion personality have significant positive effects on enterprise IS users’ voice behavior.

BackgroundImmune checkpoint inhibitors monotherapy has been studied in patients with advanced biliary tract cancer (BTC). The aim of this study was to assess the efficacy and safety of camrelizumab, plus gemcitabine and oxaliplatin (GEMOX) as first-line treatment in advanced BTC and explored the potential biomarkers associated with response.MethodsIn this single-arm, open-label, phase II study, we enrolled stage IV BTC patients. Participants received camrelizumab (3 mg/kg) plus gemcitabine (800 mg/m2) and oxaliplatin (85 mg/m2). Primary endpoints were 6-month progression-free survival (PFS) rate and safety. Secondary endpoints were objective response rate (ORR), PFS and overall survival (OS). Exploratory endpoints included association between response and tumor mutational burden (TMB), blood TMB, dynamic change of ctDNA and immune microenvironment.Results54 patients with advanced BTC were screened, of whom 38 eligible patients were enrolled. One patient withdrew informed consent before first dose treatment. Median follow-up was 11.8 months. The 6-month PFS rate was 50% (95% CI 33 to 65). Twenty (54%) out of 37 patients had an objective response. The median PFS was 6.1 months and median OS was 11.8 months. The most common treatment-related adverse events (TRAEs) were fatigue (27 (73%)) and fever (27 (73%)). The most frequent grade 3 or worse TRAEs were hypokalemia (7 (19%)) and fatigue (6 (16%)). The ORR was 80% in patients with programmed cell death ligand-1 (PD-L1) tumor proportion score (TPS) ≥1% versus 53.8% in PD-L1 TPS 0.05), except that PFS was associated with blood TMB. Patients with positive post-treatment ctDNA had shorter PFS (p=0.007; HR, 2.83; 95% CI 1.27 to 6.28).ConclusionCamrelizumab plus GEMOX showed a promising antitumor activity and acceptable safety profile as first-line treatment in advanced BTC patients. Potential biomarkers are needed to identify patients who might respond to camrelizumab plus GEMOX.Trial registration numberNCT03486678.

Objectives: This study aimed to evaluate and update incidence trends of soft-tissue sarcoma (STS) and to develop a nomogram to predict cancer-specific survival (CSS) in patients diagnosed with primary STS of the liver. Methods: Patients with hepatic STS were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Joinpoint regression analyses were performed to assess the incidence trends of STS. A nomogram was developed based on the independent risk factors chosen by Cox regression models. The calibration curve, area under the receiver operating characteristic curve (AUC), C‐index, and decision curve analysis (DCA) were used to assess the predictive performance of the nomogram. Results: The incidence of STS increased between 1994 and 2012. There was a sudden decline in the incidence of STS from 2013. The incidence of STS was different in distinct races and genders. The nomogram for predicting the CSS of hepatic STS according to the independent factors was well calibrated and it displayed optimal discrimination power. Conclusion: This study highlights that age, sex, tumor size, quality of surgery, and histologic subtypes may contribute to the prognosis of hepatic STS, and STS may be etiologically distinct and should be considered separately in different races and genders.

The impact of tumor size on account of the long-term survival results in gallbladder cancer (GBC) patients has been controversial. It is urgent necessary to identify the optimal cut-off value of tumor size in resected GBC, and we attempted to integrate tumor size with other prognostic factors into a prognostic nomogram to predict the cancer-specific survival (CSS) of GBC patients. 1639 patients with resected GBC were extracted from the Surveillance, Epidemiology and End Results (SEER) database. X-tile program was used to identify the optimal cut-off value of tumor size. A nomogram including tumor size was established to predict 1-, 3- and 5-year CSS based on the independent risk factors chosen by univariate and multivariable cox analyses. The precision of the nomogram for predicting survival was validated with Harrell’s concordance index (C-index), calibration curves, and receiver operating characteristic curve (ROC) internally and externally. Patients with GBC were classified into 1–13 mm, 14–63 mm and 64 mm subgroup based on the optimal cut-off for tumor size in terms of CSS. The nomogram according to the independent factors was well calibrated and displayed better discrimination power than 7th tumor–node–metastasis (TNM) stage systems. The results demonstrated that increased tumor size is closely associated with the worse CSS. Our novel nomogram, which outperforms the conventional TNM staging system, showed satisfactory accuracy and clinically practicality for predicting the outcome of resected GBC patients.

Background & Aims: The impact of tumor size on account of the long-term survival results in gallbladder cancer (GBC) patients has been controversial. It is urgent necessary to identify the optimal cutoff value of tumor size in resected GBC, and we attempted to integrate tumor size with other prognostic factors into a prognostic nomogram to predict the cancer-specific survival (CSS) of GBC patients. Methods 1639 patients with resected GBC were extracted from the Surveillance, Epidemiology and End Results (SEER) database. X-tile program was used to identify the optimal cutoff value of tumor size. A nomogram including tumor size was established to predict 1-, 3- and 5-year CSS based on the independent risk factors chosen by univariate and multivariable cox analyses. The precision of the nomogram for predicting survival was validated with Harrell’s concordance index (C-index), calibration curves, and receiver operating characteristic curve (ROC) internally and externally. Results Patients with GBC were classified into 1–13 mm, 14–63 mm and 64 mm subgroup based on the optimal cutoff for tumor size in terms of CSS. The nomogram according to the independent factors was well calibrated and displayed better discrimination power than 7th Tumor-Node-Metastasis (TNM) stage systems. Conclusions The results demonstrated that increased tumor size is closely associated with the worse CSS. Our novel nomogram, which outperforms the conventional TNM staging system, showed satisfactory accuracy and clinically practicality for predicting the outcome of resected GBC patients.

Background: Liver cancer is the fourth most common cause of cancer-related death and rank sixth in terms of incident cases. We aim to identify a set of miRNAs and a miRNA-based signature related to tumorigenesis and prognosis in patients with hepatocellular carcinoma (HCC). Methods: We analyzed the miRNA sequencing profiles of 373 HCC patients downloaded from The Cancer Genome Atlas LIHC program. The isoform quantification profiles were transformed into 5p and 3p mature miRNA names. Differentially expressed (DE) miRNAs between tumor and adjacent normal tissues were identified by Wald test based on the negative binomial distribution. Prognostic miRNAs associated with overall survival were confirmed by multivariate Cox proportional hazards models. The miRNA-based signatures were obtained from the linear predictors of cox regression, and the prognostic performance was compared by Harrel’s C-index and revealed by the restricted mean survival (RMS) curve. Results: The selected twelve DE miRNAs showed a good performance to classify tumor tissues from normal tissues. Meanwhile, a miRNA-based prognostic signature of eight mature miRNAs was constructed, which significantly stratified patients into high- vs low-risk groups in terms of overall survival (hazard ratio, 4.11; 95% CI, 2.71-6.24; P

High-power asynchronous machine can be used as the main generator of diesel locomotive and marine power system. The standalone power system of asynchronous generator based on four-quadrant converter is proposed. The magnetic field energy required by the machine must meet the minimum requirements for power generation, and the balance between power generation and load power must be ensured. Therefore, the initial voltage and capacitance of the DC-link capacitor are first analyzed and calculated. After that, the simple and easy slip prediction control is designed, that is, the given electric frequency takes into account the influence of the slip ratio. A power generation system is designed with an asynchronous machine as the main generator to achieve a DC voltage of 750 V, with an output power of up to 520 kW. Simulate the system for different operating conditions. The stable DC voltage is maintained under full load at different speeds. When suddenly unloading or loading 50 %, it can restore stable DC voltage in 10 ms time. In the case of stepless speed regulation and stepped speed regulation of diesel engine, the generator can still generate a stable DC voltage with loads of different power levels. The simulation results show that the power generation system has good load capacity and good dynamic performance.

Background: Liver cancer is the fourth most common cause of cancer-related death and rank sixth in terms of incident cases. With a 5-year survival of 18%, liver cancer is the second most lethal tumor, after pancreatic cancer. We aim to identify a set of miRNAs and a miRNA-based signature related to tumorigenesis and prognosis in patients with hepatocellular carcinoma (HCC). Methods: We analyzed the miRNA sequencing profiles of 373 HCC patients downloaded from The Cancer Genome Atlas LIHC program. The isoform quantification profiles were transformed into 5p and 3p mature miRNA names. Differentially expressed (DE) miRNAs between tumor and adjacent normal tissues were identified by Wald test based on the negative binomial distribution. Prognostic miRNAs associated with overall survival were confirmed by multivariate Cox proportional hazards models. The miRNA-based signatures were obtained from the linear predictors of cox regression, and the prognostic performance was compared by Harrel’s C-index and revealed by the restricted mean survival (RMS) curve. Findings: The selected twelve DE miRNAs showed a good performance to classify tumor tissues from normal tissues. Meanwhile, a miRNA-based prognostic signature of eight mature miRNAs was constructed, which significantly stratified patients into high- vs low-risk groups in terms of overall survival (hazard ratio, 4.11; 95% CI, 2.71-6.24; P

Based on knowledge map and bibliometric analysis, this paper uses 1484 Chinese paper in the field of organizational citizenship behavior collected by China Knowledge Network database from 2000 to 2019 as samples, and uses Sati, Ucient and Citespace software for quantitative analysis. Price law, Lotka's law and Bradford's law analysis results show that the research in this field has not formed a core research author group, but a core journal group. In addition, the keyword clustering results also reflect the four main categories of research topics: antecedents, outcomes, dimensions, and behavioral types, while compulsory organizational citizenship behavior is the hot spot and frontier at present and in the future.

Users' behavior is a key effect factor of successful application of IT. However, extant research has focused on the in-role behaviors such as IT adoption and routine IT usage, while the research on users' innovative use of IT which belongs to extra-role behaviors is still limited. Based on the research gap of innovative use of IT at the individual level and work competence theory, this paper analyzed the antecedents of innovative use of IT. Hypotheses are proposed and tested with the data collected by a survey of 156 ERP users. The results show that attitude towards innovation, IT application knowledge, extraversion, and management support have important effects on innovative use of IT at the individual level. Implications of the research results are discussed.

Recently, patients with advanced cancers have been benefited greatly from immune checkpoint blockade immunotherapy. However, immune checkpoint blockade is still suboptimal in HCC treatment and more immune modifications are needed to achieve an efficient therapeutic goal. Here, we investigated the combined administration of a Listeria-based HCC vaccine, Lmdd-MPFG, and the anti-PD-1 immune checkpoint blockade antibody. We found that Lmdd-MPFG promoted the expression of PD-L1 in HCC cells but resensitized the tumor local T cell to respond to the anti-PD-1 immunotherapy. Mechanistically, the Lmdd-MPFG vaccine activates the NF-κB pathway in the tumor-associated macrophages (TAMs) through the TLR2 and MyD88 pathway, and recruits p62 to activate the autophagy pathway. The overall effect is skewing the TAMs from M2-polarized TAMs into the M1-polarized TAMs. Most importantly, it skewed the cytokine profiles into antitumor one in the tumor microenvironment (TME). This change restores the T-cell reactivity to the anti-PD-1 blockade. Our results suggested that Lmdd-MPFG combined with PD-1 blockade exerted synergistic antitumor effects through modifying TAMs in the TME and removing T-cell inhibitory signals, thereby providing a new potential strategy for HCC treatment.

e16146 Background: The synergic combination of anti-PD-1/PD-L1 and antiangiogenic agents has exhibited as an encourage treatment pattern in aHCC. Multi-targeted antiangiogenic TKIs, such as lenvatinib and sorafenib, are approved for 1st-line treatment of aHCC. Sintilimab, a novel selective anti-PD-1 monoclonal antibody, has demonstrated encouraging clinical activities in aHCC. The trial aims to explore the safety and efficacy of sintilimab plus anlotinib (a TKI against angiogenesis) in aHCC. Methods: This is a single-arm phase 2 study. Eligible Pts with aHCC, BCLC stage C or B (not amenable for surgery and chemoembolization), Child-Pugh scores≤7 and ECOG PS ≤ 1 received 1st-line treatment of sintilimab (200mg, iv, D1) plus anlotinib (12mg, po, QD, D1-14) every 3 wks until disease progression or unacceptable toxicity. Primary endpoints were safety and objective response rate (ORR, per RECIST 1.1), and secondary endpoints included disease control rate (DCR), progression free survival (PFS), duration of response (DOR) and overall survival (OS). Results: As of January 15, 2021, 20 pts were enrolled (males 18 ; median age 56 yrs [range 41-70] ; BCLCB/C: 5/15 ; Child-Pugh A/B7: 19/1 ; HBV infection 20). All pts received at least two cycles of treatments with median cycles 7.5 [range 2-22]. Median follow-up was 12 months [range 3-19]. The most common treatment-related adverse events (TRAEs) were grade 1-2 with thrombocytopenia (45.0%), hand-foot syndrome (40.0%), hypertension (35.0%), increased AST (35.0%), ALT (30.0%), decreased neutrophil count (25.0%), leukopenia (25.0%). 8 pts experienced manageable grade 3 TRAEs, and no grade 4/5. 12 pts required dose reduction of anlotinib (9 pts to 10 mg and 3 to 8 mg). No treatment withdraw caused by TRAEs. ORR was 40.0% (8/20) with 1 CR and 7 PR, 11 pts were SD, and DCR was 95.0% (19/20). Median DoR was not reached. 6m-PFS rate was 66.4% (95%CI: 47.7%-92.5%), immature median PFS was 14.65 months (95%CI: 5.06 -not reached) with 8 events. Conclusions: The combination of sintilimab and anlotinib showed promising clinical activities with manageable toxicity for first line treatment of aHCC. Clinical trial information: NCT04052152. Research Sponsor: Innovent Biologics, Inc., Chia-Tai Tianqing Pharmaceutical Group Co Ltd. Clinical trial information: NCT04052152.

536 Background: We conducted a trial to evaluate the efficacy and safety of SHR-1210 (a humanized anti-programmed cell death receptor 1 antibody) plus gemcitabine and oxaliplatin (GEMOX) as in untreated patients (pts) with biliary tract cancer (BTC) (NCT03486678). This study is to explore the predictive biomarkers for efficacy. Methods: Baseline lymphocyte count and lactate dehydrogenase (LDH) level were obtained from routine tests. Gene mutation and tumor mutation burden (TMB) from baseline tissue and blood samples were tested by the next generation sequencing (NGS) with a 425-gene panel. The expressions of PD-L1 and markers for lymphocyte, natural killer cells, and macrophages in baseline tumor tissue samples were analyzed by immunohistochemistry (IHC). Results: The median progression free survival (PFS) and overall survival (OS) in this trial was 6.2m and 12.1m, respectively. Firstly, pts with normal LDH level (≤271 U/L) had a tendency for longer PFS (6.2m vs 5.0m, p = 0.053) and significantly longer OS (p = 12.6m vs 6.8m, p < 0.001) than those with elevated LDH ( > 271 U/L). Low baseline lymphocyte count (≤ 1.1×109/L) was related to worse OS (12.6m vs 6.9m, p < 0.001) and PFS (6.2m vs 3.9m, p = 0.021). Secondly, baseline tissue and ctDNA gene mutations were detected in 33 and 30 pts, respectively. Tissue analysis showed that pts with STK11 (p = 0.0254), CTNNB1 (p < 0.001) and SMARCA4 (p = 0.0181) wild type showed significantly longer PFS than those with mutations. Pts with ARID1A gene wild type showed a tendency for longer PFS (p = 0.0634) and significantly longer OS (p = 0.0149). Gene mutations from baseline ctDNA revealed that pts with wild type SMARCA4, CTNNB1, STK11, and NF1 had longer PFS than those with mutations. Lastly, IHC meant that PD-L1 positivity may be related to longer PFS (TPS > 1%, p = 0.08; IPS > 1%, p = 0.05). Besides, pts with CD68+ HLA-DR+ macrophages > 0.01%, CD68+ HLA-DR- macrophages>2.5%, and CD56bright>1.7% and CD56dim > 0.05 also got PFS benefits (all p < 0.05). TMB (cutoff = 7 muts/mbp) was not associated with PFS. Conclusions: Despite limited sample size, biomarkers from routine blood test, gene mutation and immune microenvironment can be helpful to stratify pts who are sensitive to immunotherapy in advanced BTC. Clinical trial information: NCT03486678.

535 Background: This study aimed to evaluate the efficacy and safety of SHR-1210 (a humanized anti-programmed cell death receptor 1 antibody) plus gemcitabine and oxaliplatin (GEMOX) as first line treatment in patients (pts) with biliary tract cancer (BTC). Methods: This was a single-arm, single-center, exploratory trial, which included advanced BTC pts. Pts received SHR-1210 (3mg/kg, total dose ≤200mg, ivd, D1/2W) combined with gemcitabine (800 mg/m2, ivd, D1/2W) and oxaliplatin (85mg/m2, ivd, D2/2W). Combined chemotherapy lasted for no more than 12 cycles. Once chemotherapy intolerance occurred or at end of 12-cycle combined chemotherapy, pts with stable disease or objective response would continue to take SHR-1210 as single agent until disease progression or intolerable toxicity. The primary endpoint was the 6-month progression free survival (PFS) rate. Results: From February 2018 to April 2019, 37 eligible pts were enrolled. The median age was 64 (range 41-74) years, male/female was 70.3/29.7%, and bile duct cancer/gallbladder cancer was 59.5/40.5%. All 37 pts were included in the safety analysis. The overall AE incidence rate was 97.3%. The incidence of grade ≥3 AEs was 73.0%, which mainly included increased GGT (gammaglutamyltransferase, 18.9%), hypokalemia (18.9%), and fatigue (16.2%). Particularly, the incidence of fever is 73.0%, in which 2 pts experienced grade 3/4 fever. Among 36 evaluable pts, 19 pts got partial response (PR, 52.8%), 14 pts stable disease (SD, 38.9%), and 3 pts progressive disease (PD, 8.3%) at best. The primary endpoint 6-month PFS rate was 50.0% (95% CI 32.4-65.4), which indicated that the primary endpoint of the study was reached, and mPFS was 6.2 months (95% CI 4.2-7.1). The 12-month overall survival (OS) rate was 50.5% (95% CI 30.6-67.4), and mOS was 12.1 months (95% CI 8.0-NA). Conclusions: This study has reached the pre-defined primary endpoint with a high response rate. Predictive biomarker analysis was reported in another abstract. Further study is needed to validate the efficacy of this combination. Clinical trial information: NCT03486678.

In the presence of arbitrary array errors and angle mismatch, performance on target detection and angle estimation will be degraded due to steering vector mismatch. Thus, a robust target detection and estimation algorithm for airborne STAP radar is developed. First, utilizing the spatial-temporal coupling property of the ground clutter, array steering vectors are well estimated by fine Doppler localization of the mainlobe clutter. Then, the robust subspace detector spanned by these estimated array steering vectors is developed, which can improve the detection performance for the targets not located in the look direction. Finally, target angle estimation using subspace coefficients, which implements the ML estimator in a reduced-dimensional version, is presented to reduce the computational complexity of the ML estimator. Numerical examples are given to demonstrate the effectiveness of the presented algorithm.

Since the introduction of Electrical Multiple Units (EMUs) to China, traction control technology has become one of the study hotspots. The traction control system of EMUs consists of a traction converter system and a Traction Control Unit (TCU). The traction converter system is composed of a transformer, a four-quadrant pulse rectifier, intermediate DC link, rheostatic chopper, a three phase half bridge inverter and an induction motor. The traction control unit is the brain of the whole system. It controls rectifier, chopper and inverter according to the signals which come from sensors and orders which come from the Center Control Unit (CCU). By reference to the voltage range of the traction system in CRH5, the traction and control system is constructed. And TCU is designed to have hierarchic structure. Then the whole system is simulated. In the system the rectifier is controlled by the theory of transient current control with SPWM (Sinusoidal Pulse Width Modulation) technology. The chopper is used to control filter voltage as a soft crowbar. In the inverter the indirect rotor flux oriented vector control theory with current hysteretic band PWM strategy is adopted. Interface which refers to driver control desk is completed with GUI (Graph User Interface) tool in Matlab. Through the interface EMUs' speed and traction effort are set and the real speed is shown. Both traction control and constant speed control of EMUs are simulated based. The results present that the system has the advantage of good dynamic and steady state performance. And the system is useful for study the performance of the whole system with various control strategies.

Ontology evolution in collateral environments mainly features that multiple users modify the same ontology. All of the ontology change sequences submitted by the users may not be done to the ontology because there are conflicts between them. Unlike previous approach that some ontology change sequences must be removed, this paper focuses on the relationship between ontology changes rather than ontology change sequences. We defined a dependence relationship between two ontology changes and searched all the dependences from different ontology change sequences. We constructed a direct graph for ontology changes with the dependences set. On this basis, we proposed an algorithm based on Traveling Salesmen Problem to find a suitable evolution path. A prototype is implemented and the experiment showed that our approach could keep more ontology changing.

UIC gateway built on UIC556 standard can realize inauguration, process and message data effective configuration and communication between different manufacturers EMUs. With valid configuration of node monitoring database, process data can be properly transferred to the WTB (MVB) bus through filtering and operating of process data marshalling. In this paper, comprehensive and detailed analysis of communication theory and software framework of process data was given within the EMU UIC gateway. In view of the process data transmission routing, marshalling operation procedure and treatment method were studied. By semi-physical simulation platform, the theory above was simulated and functional verified.

UIC556 standard formulates the mechanism and mode of inauguration, process data and message data communication in the UIC gateway of electric multiple unit (EMU) trains detailed. The UIC Gateway is the basic component for communication in trains. As the main EMU communication data stream, process data and message data must be effectively processed and converted with the help of the node monitoring database configuration, then can be transferred to the WTB (MVB) bus correctly. In this paper, comprehensive and detailed analysis of communication theory and software architecture of process data and message data were given in the UIC gateway of EMU. Two important media of process data and message data within the gateway are process data marshalling and UIC mapping server. Process data marshalling mainly achieve filtering and calculation of data between WTB and MVB, marshalling type, operating procedures and marshalling framework were deeply researched. UIC mapping server and TCN protocol stack provide the best path and a variety of services. The transmission mechanism of message data in the gateway and the composition and function of each part of UIC mapping server were detailed analyzed. By semi-physical simulation platform, the theory above is simulated and verified.

The traction converter system of EMU is constructed based on Matlab/Simulink. The system consists of a transformer, a rectifier, an inverter and an induction motor. The rectifier is controlled by the transient current control theory with SPWM technology. In the inverter the indirect vector control theory with current hysteretic band PWM strategy is adopted. Based on the system the traction control and constant speed control are tested. The simulation results present that the system is with good dynamic and steady state performance and fulfill the running demand of EMU.

This study was aimed to compare and evaluate the diagnostic performance of non-contrast-enhanced MR angiography (NCE-MRA) with contrast-enhanced MR angiography (CE-MRA) in the anatomic assessment of hepatic portal vein. Thirty people, ten patients with hepatic cirrhosis without ascites and twenty normal physical examination donors as control group were included in the NCE-MRA and CE-MRA with the same 1.5T MR scanner. Anatomic angiographic images were reconstructed and their datasets available for analysis independently performed by two radiologists. Assessment of data quality of hepatic portal vein vessels was rated with a four-point scale. After consensus reading, a total 27 images (90%) scored more than 3 point were observed in NCE-MRA and 28 (93.3%) in CE-MRA, respectively. Segmental branch vessels were visualized on MR angiography in the majority of cases. Both NCE-MRA and CE-MRA correctly characterized the hepatic portal veins with grade 5 and without false positive cases. Only 4 false negatives with grade 6 were missed in NCE-MRA group. There were no statistically significant differences between NCE-MRA and CE-MRA for characterization of hepatic vasculature (P0.05). Kappa value was larger than 0.75 for both reviewers. A conclusion could be drawn that NCE-MRA is a non-invasive and effective method that provides a comprehensive assessment of the hepatic portal vein.